Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Maine Rx Negotiations With Manufacturers Continue After Court Ruling

  • News

Executive Summary

Maine will delay enrollment for its prescription drug discount program while the state Department of Human Services attempts to reach additional discount agreements with drug manufacturers.

You may also be interested in...



Supreme Court Allows Maine Rx; PhRMA Says States Will Delay Similar Plans

The Pharmaceutical Research & Manufacturers of America believes that until Maine issues regulations to implement Maine Rx, other states will wait before proceeding with similar programs

Supreme Court Allows Maine Rx; PhRMA Says States Will Delay Similar Plans

The Pharmaceutical Research & Manufacturers of America believes that until Maine issues regulations to implement Maine Rx, other states will wait before proceeding with similar programs

PhRMA v. Maine: Supreme Court Suggests HHS Should Review Maine Rx

Several Supreme Court justices appear interested in hearing HHS' opinion on whether the Maine Rx program should proceed

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS036820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By